Hypertrophie ventriculaire gauche chez les hémodialysés : prévalence, étude électrique, échographique et facteurs de risque

Chargui, S.; Allouche, E.; Dkhil, Wiem; Agrebi, S.; Ahmed, Habib Ben; Ezzaouia, K.; Hajji, M.; Ezzamouri, Asma; Basdah, Leila; Hamida, F. Ben; Abderrahim, E.

doi:10.1016/j.nephro.2021.10.003

Cited by 2 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most apparent relationship between anaemia and cardiac disease is left ventricular hypertrophy (LVH) [2,3]. The prevalence of LVH in HD patients is as high as 61%-75% [4,5], and LVH is a significant predictor of cardiovascular mortality and morbidity in these patients. It is an independent risk factor for the development of arrhythmias, sudden death, heart failure and ischaemic heart disease, which sharply increases the risk of sudden cardiac death.…”

Section: Introductionmentioning

confidence: 99%

Roxadustat reduces left ventricular mass index compared to rHuEPO in haemodialysis patients in a randomized controlled trial

Tan,

Wang,

Sun

et al. 2024

J Intern Med

View full text Add to dashboard Cite

BackgroundLeft ventricular hypertrophy (LVH) is highly prevalent in haemodialysis (HD) patients and is associated with an increased risk of death. Roxadustat and recombinant human erythropoietin (rHuEPO, abbreviated as EPO) are the main treatment strategies for renal anaemia in HD patients, but it has not been clear whether there is a difference in their effect on LVH.MethodsIn this multi‐centre, prospective, randomized trial of 12‐month duration, study participants were randomized in a 1:1 ratio to the roxadustat group or the EPO group. The doses of both treatment regimens were adjusted so that the patients had a haemoglobin level of 10.0–12.0 g per dL. The primary study endpoint was the change from baseline to 12 months in the left ventricular mass index (LVMI, g/m2) measured by echocardiography.ResultsIn total, 114 patients were enrolled. The mean age was 50 years, and the median dialysis duration was 33 months. Sixty‐one patients were men, and 24 were diabetic. LVMI decreased from 116.18 ± 27.84 to 110.70 ± 25.74 g/m2 in the roxadustat group. However, it increased from 109.35 ± 23.41 to 114.99 ± 28.46 g/m2 in the EPO group, with a significant difference in the change in LVMI between the two groups [−5.48 (−11.60 to 0.65) vs. 5.65 (0.74 to 10.55), p < 0.05]. Changes in left ventricular mass, end‐diastolic volume and 6‐min walk test seemed superior in the roxadustat group. There were no significant differences in other cardiac geometry, biochemical parameters and major adverse cardiovascular events between the two groups.ConclusionsCompared to EPO, roxadustat is more helpful in the regression of LVH in HD patients.

show abstract